Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

Monitor Adverse Events Clinical Trial

Official title: Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Prostate Cancer After Non-Myeloablative Conditioning

Status Suspended

Clinical Trial Summary

This is a Phase Ib Pilot study of anti-PSMA designer T cells in metastatic prostate cancer. Subjects will receive escalating doses of T cells, with either low or moderate dose Interleukin 2. The T cells are collected by pheresis and then genetically modified, and given in a one time infusion.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Monitor Adverse Events

• NCT number: NCT01929239
• Study type: Interventional
• Source: Roger Williams Medical Center
• Status: Suspended
• Phase: Phase 1/Phase 2
• Start date: March 2006
• Completion date: December 2018